ERBB2 and breast cancer: Olaparib and talazoparib are examples of PARPi that the FDA and EMA (European Medicines Agency) have approved to treat patients with locally advanced and metastatic BC in patients with deleterious or suspected deleterious germline BRCA (gBRCA)-mutated HER2-BC [101].